NCT01255748 Registry Study for Radiation Therapy Outcomes
| NCT ID | NCT01255748 |
| Status | Recruiting |
| Phase | — |
| Sponsor | Proton Collaborative Group |
| Condition | Neoplasms |
| Study Type | OBSERVATIONAL |
| Enrollment | 50,000 participants |
| Start Date | 2009-06 |
| Primary Completion | 2039-06 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
This is an observational study. You will not receive an experimental treatment; researchers will collect data based on your existing condition or standard treatment.
This trial targets 50,000 participants in total. It began in 2009-06 with a primary completion date of 2039-06.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
The purpose of this research study is to collect and analyze information from patients being treated with various forms of radiation therapy.
Eligibility Criteria
Inclusion Criteria: * Planned treatment with radiation therapy * Ability to understand and sign IRB approved consent
Contact & Investigator
Carlos Vargas, MD
STUDY CHAIR
Proton Collaborative Group
Frequently Asked Questions
Who can join the NCT01255748 clinical trial?
This trial is open to participants of all sexes, studying Neoplasms. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT01255748 currently recruiting?
Yes, NCT01255748 is actively recruiting participants. Visit ClinicalTrials.gov or contact Proton Collaborative Group to inquire about joining.
Where is the NCT01255748 trial being conducted?
This trial is being conducted at Scottsdale, United States, Little Rock, United States, San Diego, United States, Delray Beach, United States and 11 additional locations.
Who is sponsoring the NCT01255748 clinical trial?
NCT01255748 is sponsored by Proton Collaborative Group. The principal investigator is Carlos Vargas, MD at Proton Collaborative Group. The trial plans to enroll 50,000 participants.